Repligen (RGEN) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
15 May, 2026Opening remarks and agenda
Meeting opened virtually to ensure accessibility for all shareholders worldwide.
Chair introduced the agenda and directed participants to the virtual meeting website for materials and rules of conduct.
Introductions included board members, executive team, independent auditor, and inspector of elections.
Board and executive committee updates
Board members and executive officers were introduced, including the President and CEO, CFO, and General Counsel.
Shareholder proposals
Three proposals were presented: election of nine directors, ratification of Ernst & Young as auditor, and a non-binding advisory vote on executive compensation.
Board recommended voting in favor of all proposals.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Repligen
- Q2 2026 revenue up 13% organically, margins expanded, and $1.5B BioLife deal announced.RGEN
Q2 202629 Jul 2026 - $1.5B acquisition accelerates cell therapy leadership, delivers synergies, and targets Q4 2026 close.RGEN
M&A announcement22 Jul 2026 - Innovation and strategic expansion drive optimism for double-digit growth and margin recovery.RGEN
2024 Wells Fargo Healthcare Conference9 Jul 2026 - Strong Q3 growth, minimal US vaccine exposure, and margin expansion expected in 2025.RGEN
Stifel 2024 Healthcare Conference8 Jul 2026 - Q3 2025 saw 22% revenue growth, margin gains, and raised guidance amid global strength.RGEN
Q3 20258 Jul 2026 - Q2 2025 revenue grew 15% with 17% organic non-COVID growth and raised full-year guidance.RGEN
Q2 20258 Jul 2026 - Q3 revenue up 10% to $155M, with strong CDMO growth, improved margins, and pending acquisition.RGEN
Q3 20248 Jul 2026 - Robust growth, margin expansion, and strategic investments position the business for long-term gains.RGEN
UBS Global Healthcare Conference 20258 Jul 2026 - 2024 revenue and orders rebounded, with 2025 guidance targeting double-digit growth and margin gains.RGEN
Q4 20248 Jul 2026 - Innovation and APAC expansion drive growth, with FY26 revenue guided at $803M–$833M.RGEN
46th Annual William Blair Growth Stock Conference3 Jun 2026